Loading...

News List

百吉生物获批启动TCR细胞疗法 I 期临床试验

2023-09-13


2023年9月9日,Biosyngen Pte Ltd (以下简称“Biosyngen”百吉生物)宣布美国 FDA 已批准 I/II 期临床研究新药 (IND) 申请BRL03治疗肺癌、胃癌等晚期实体瘤的试验公司第三个一线疗法BRL03的获批。

值得注意的是,BRL03也是百吉生物开发的第一个进入临床试验的TCR-T产品。这一重大成就得益于公司的前沿技术以及多年来能力和资源的广泛积累。

BRL03是一种 T 细胞受体 (TCR) 疗法,可分离患者的 T 细胞,然后对其进行基因改造以靶向特定细胞抗原。然后将这些经过修饰的 T 细胞输回患者体内。


Pre: Researchers at Zhejiang University School of Medicine have revealed that the concept of targeting DDK can improve the efficacy of immunotherapy for liver cancer

Next: Bagel Biologics receives approval to initiate Phase I clinical trial of TCR cell therapy

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.